Discounted Cash Flow (DCF) Analysis Levered
Abbott Laboratories (ABT)
$101.69
+0.91 (+0.90%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 30,578 | 31,904 | 34,608 | 43,075 | 43,653 | 47,867.61 | 52,489.12 | 57,556.84 | 63,113.83 | 69,207.34 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | 6,300 | 6,136 | 7,901 | 10,533 | 9,581 | 10,441.51 | 11,449.61 | 12,555.05 | 13,767.21 | 15,096.41 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -1,394 | -1,638 | -2,177 | -1,885 | -1,777 | -2,338.84 | -2,564.65 | -2,812.26 | -3,083.78 | -3,381.51 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | 4,906 | 4,498 | 5,724 | 8,648 | 7,804 | 8,102.67 | 8,884.97 | 9,742.79 | 10,683.44 | 11,714.90 |
Weighted Average Cost Of Capital
Share price | $ 101.69 |
---|---|
Beta | 0.663 |
Diluted Shares Outstanding | 1,786 |
Cost of Debt | |
Tax Rate | 16.53 |
After-tax Cost of Debt | 1.29% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 6.874 |
Total Debt | 24,295 |
Total Equity | 181,618.34 |
Total Capital | 205,913.34 |
Debt Weighting | 11.80 |
Equity Weighting | 88.20 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 30,578 | 31,904 | 34,608 | 43,075 | 43,653 | 47,867.61 | 52,489.12 | 57,556.84 | 63,113.83 | 69,207.34 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | 6,300 | 6,136 | 7,901 | 10,533 | 9,581 | 10,441.51 | 11,449.61 | 12,555.05 | 13,767.21 | 15,096.41 |
Capital Expenditure | -1,394 | -1,638 | -2,177 | -1,885 | -1,777 | -2,338.84 | -2,564.65 | -2,812.26 | -3,083.78 | -3,381.51 |
Free Cash Flow | 4,906 | 4,498 | 5,724 | 8,648 | 7,804 | 8,102.67 | 8,884.97 | 9,742.79 | 10,683.44 | 11,714.90 |
WACC | ||||||||||
PV LFCF | 7,182.86 | 7,415.83 | 7,656.35 | 7,904.67 | 8,161.05 | |||||
SUM PV LFCF | 40,700.48 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 6.21 |
Free cash flow (t + 1) | 11,949.20 |
Terminal Value | 283,828.92 |
Present Value of Terminal Value | 210,004.98 |
Intrinsic Value
Enterprise Value | 250,705.46 |
---|---|
Net Debt | 14,413 |
Equity Value | 236,292.46 |
Shares Outstanding | 1,786 |
Equity Value Per Share | 132.30 |